Literature DB >> 18973068

NRAMP1 polymorphism and viral factors in Sardinian multiple sclerosis patients.

Maria Gazouli1, Leonardo Sechi, Daniela Paccagnini, Stefano Sotgiu, Giannina Arru, George Nasioulas, Dimitrios Vassilopoulos.   

Abstract

BACKGROUND: Multiple sclerosis (MS) is believed to be an autoimmune disease occurring in genetically predisposed individuals after an appropriate environmental exposure such as viral infections. Recent studies suggest a significant association between MS and the functional 5'-(GT)n polymorphism in the promoter region of the NRAMP1 gene. In the present study we aimed to evaluate the contribution of the allelic variation in the NRAMPI promoter to MS susceptibility and to study the role of viral infection in relation to specific NRAMP1 genotypes, in a Sardinian cohort.
METHODS: Sixty MS patients and 66 healthy individuals were genotyped, and screened for the presence of Epstein-bar virus (EBV) and JC virus (JCV) sequences.
RESULTS: Consistent with previous autoimmune disease studies, allele 3 at the functional 5'(GT)n promoter region repeat polymorphism, was significantly overrepresented among MS patients when compared to controls (p=0.02). The EBV and JCV sequences were detected in 8/60 (13.33%) and in 4/60 (6.66%) of MS patients respectively and in 5/66 (7.57%) and in 0/66 of controls.
CONCLUSION: The allelic variation in the NRAMP1 promoter may contribute to MS susceptibility in the Sardinian population. The viral sequences were not confined to a specific NRAMP1 genotype.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18973068     DOI: 10.1017/s0317167100009173

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  9 in total

1.  The functional SLC11A1 gene polymorphisms are associated with sarcoidosis in Turkish population.

Authors:  Pinar Akçakaya; Benura Azeroglu; Ipek Even; Omer Ates; Hatice Turker; Gul Ongen; Aysegul Topal-Sarikaya
Journal:  Mol Biol Rep       Date:  2011-12-08       Impact factor: 2.316

Review 2.  Pathogenic implications of iron accumulation in multiple sclerosis.

Authors:  Rachel Williams; Cassandra L Buchheit; Nancy E J Berman; Steven M LeVine
Journal:  J Neurochem       Date:  2011-11-11       Impact factor: 5.372

3.  NRAMP1 (SLC11A1) variants: genetic susceptibility to multiple Sclerosis.

Authors:  Omer Ates; Semiha Kurt; Nihan Bozkurt; Hatice Karaer
Journal:  J Clin Immunol       Date:  2010-04-20       Impact factor: 8.317

4.  M. paratuberculosis Heat Shock Protein 65 and Human Diseases: Bridging Infection and Autoimmunity.

Authors:  Coad Thomas Dow
Journal:  Autoimmune Dis       Date:  2012-09-29

Review 5.  The conundrum of iron in multiple sclerosis--time for an individualised approach.

Authors:  Susan J van Rensburg; Maritha J Kotze; Ronald van Toorn
Journal:  Metab Brain Dis       Date:  2012-03-17       Impact factor: 3.584

6.  Association of Mycobacterium avium subsp. paratuberculosis with multiple sclerosis in Sardinian patients.

Authors:  Davide Cossu; Eleonora Cocco; Daniela Paccagnini; Speranza Masala; Niyaz Ahmed; Jessica Frau; Maria Giovanna Marrosu; Leonardo A Sechi
Journal:  PLoS One       Date:  2011-04-13       Impact factor: 3.240

7.  Natural history of SLC11 genes in vertebrates: tales from the fish world.

Authors:  João V Neves; Jonathan M Wilson; Heiner Kuhl; Richard Reinhardt; L Filipe C Castro; Pedro N S Rodrigues
Journal:  BMC Evol Biol       Date:  2011-04-18       Impact factor: 3.260

Review 8.  Mycobacterium avium ss. paratuberculosis Zoonosis - The Hundred Year War - Beyond Crohn's Disease.

Authors:  Leonardo A Sechi; Coad Thomas Dow
Journal:  Front Immunol       Date:  2015-03-04       Impact factor: 7.561

9.  Human neural precursor cells promote neurologic recovery in a viral model of multiple sclerosis.

Authors:  Lu Chen; Ronald Coleman; Ronika Leang; Ha Tran; Alexandra Kopf; Craig M Walsh; Ilse Sears-Kraxberger; Oswald Steward; Wendy B Macklin; Jeanne F Loring; Thomas E Lane
Journal:  Stem Cell Reports       Date:  2014-05-15       Impact factor: 7.765

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.